CAI

Caris Life Sciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 12:40 UTC

Last close

25.23USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-03-03

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
21.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
-8.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
8.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
0.74Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-11-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.08 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.12x

0.88x

-0.31x

0.33x

1.01x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales2.12x
Its own average over 10 years, 382.4M.
Profit0.88x
Its own average over 10 years, -77.0M.
Free cash flow-0.31x
Its own average over 10 years, -216.5M.
Debt0.33x
Its own average over 9 years, 1.30B.
Price1.01x
Its own average over 2 years, 25. Market data, 2026-11-06

Free cash flow is furthest from its own average, at -0.31 times.

Sales is 2.12 times its own 10-year average; Profit is 0.88 times its own 10-year average; Free cash flow is -0.31 times its own 10-year average; Debt is 0.33 times its own 9-year average; Price is 1.01 times its own 2-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales against its own 10-year average2.12
Source
filed
Statement
income
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
The filing itself
Profit against its own 10-year average0.88
Source
filed
Statement
income
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
The filing itself
Free cash flow against its own 10-year average-0.31
Source
filed
Statement
income
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
The filing itself
Debt against its own 9-year average0.33
Source
filed
Statement
income
Fiscal year
2025
Accession
0002019410-26-000016
Reported in
USD
The filing itself
Price against its own 2-year average1.01Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD